Finance1 min read

Tandem Diabetes shares climb 5% after Stifel upgrades stock to Buy

By · Via Investing.com Markets · Published by Everything Blog

In short

The stock advanced following an improved assessment delivered by Stifel research analysts. Market participants reacted to the firm changing its stance directly to a Buy rating. This broker upgrade drove a five percent gain in the company's equity value.

Key points

  • Analyst rating improvements can drive prompt positive reactions in medical device equitie…: Analyst rating improvements can drive prompt positive reactions in medical device equities.
  • Stifel holds a constructive outlook on Tandem Diabetes shares after the upgrade.: Stifel holds a constructive outlook on Tandem Diabetes shares after the upgrade.
  • The equity experienced a five percent jump directly tied to Wall Street coverage.: The equity experienced a five percent jump directly tied to Wall Street coverage.
Finance